At a Glance
- Company: Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, Veradermics; Generate Biomedicines
- Locations: US and European biotech issuers
- Headline: Four IPOs raising close to $1bn combined; biotech IPOs hit 15‑year low in 2025
- Focus area: Early‑ to mid‑stage drug developers across multiple therapeutic areas
- Next steps: Watch how these stocks trade post‑IPO as a barometer for sector sentiment
What happened?
A STAT analysis describes how the long‑dormant biotech IPO market showed signs of life as four drugmakers — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public in the same week, raising close to $1 billion in total. A fifth company, AI‑driven Generate Biomedicines, filed for an IPO, adding further momentum to what could be a turning point for biotech equity financing.
Why does it matter?
Biotech IPOs had largely dried up after a 2021 peak, with only 11 companies going public last year — the lowest tally in 15 years — as macro conditions, policy uncertainty and risk‑off sentiment kept investors away. The cluster of sizeable offerings suggests that, at least for select names with compelling stories or later‑stage assets, the public markets may be starting to open again, offering an alternative to private rounds and pharma deals.
Who’s behind it?
The new cohort spans a mix of platform and product‑focused companies, from Eikon’s advanced imaging‑based drug discovery to ophthalmology‑focused Spyglass and dermatology player Veradermics. Generate Biomedicines, backed by Flagship Pioneering, represents the AI‑enabled end of the spectrum, aiming to float as one of the first high‑profile AI‑biotechs of 2026.
How was it achieved?
These offerings came together as general markets stabilised, interest‑rate expectations shifted and specialist biotech investors looked for new opportunities after years of depressed valuations. The article frames the week’s IPOs as both a reflection of improving sentiment and a test of how much risk investors are truly willing to underwrite in an industry still grappling with high R&D costs and binary clinical outcomes.
What’s next?
The real test for the sector will be how these newly listed biotechs trade in the coming months — whether they can hold or grow their valuations, and whether follow‑on offerings are possible. If performance holds up, more venture‑backed drug developers, including AI and modality‑focused platforms, may accelerate IPO plans, potentially turning a tentative rebound into a more sustained reopening of the biotech equity window.
What are people saying?
STAT characterises the resurgence as part of a broader “turnaround story” for biotech, but stresses that it is early days and that the IPO market remains selective rather than wide open.